Back to Search
Start Over
A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma.
- Source :
-
Cancer Investigation . May2008, Vol. 26 Issue 3, p269-277. 9p. 3 Charts, 4 Graphs. - Publication Year :
- 2008
-
Abstract
- Dose-dense temozolomide schedules deplete O6-methylguanine methyltransferase and may overcome chemoresistance. This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles. Six-month progression-free survival was 56%, comparing favorably with historic controls treated with the standard 5-day temozolomide schedule. Median survival was 12.9 months (95% CI: 3.7, 22 months). Among 15 evaluable patients, 2 had a complete or partial response, and 10 had stable disease. Grade 3 and 4 lymphopenia occurred in 53% and 47% of patients, respectively. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 07357907
- Volume :
- 26
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Cancer Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 31159654
- Full Text :
- https://doi.org/10.1080/07357900701708393